COMPANY
Tallac Therapeutics
Timeline
- Trial start Phase 1/Phase 2: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05399654 | A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Jun 28, 2022 | Jan 27, 2026 (estimated) |